Acclarent Pays $18m To Settle False-Claims Allegations
Executive Summary
The one-time payment will put to rest government claims that Acclarent marketed its Relieva Stratus device for off-label use. Two former Acclarent execs were found guilty of misdemeanors last week in a related case.
You may also be interested in...
Acclarent Execs Move To Appeal Off-Label Conviction
Attorneys for former Acclarent executives William Facteau and Patrick Fabian have filed a request that their convictions on off-label marketing charges either be set aside or that they be granted a new trial, citing other recent off-label trials and misconduct by the government.
Former Acclarent Execs Convicted Of Misdemeanors In Off-Label Case
Two former executives from J&J's Acclarent division were found not guilty of felony charges but convicted on misdemeanor counts. Prior to being acquired by J&J, Acclarent allegedly marketed its Relieva Stratus sinus dilation device as a steroid-delivery system, even though the FDA had cleared the device only to deliver saline.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.